mph Bangladesh


(all mi sar' tan) 

PCI - Contraindicated in pregnancy

LCaution when used during lactation - Caution when used during lactation

Molecule Info




  • When pregnancy is detected, discontinue Olmesartan as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Indication(s) & Dosage

HYPERTENSION  Adult: Initial: 10-20 mg once daily. Antihypertensive effect is substantially present within 2 wk of therapy initiation.  Dose may be increased up to 40 mg once daily if needed.  May consider a lower starting dose in patients with possible depletion of intravascular volume.  Child: 6 to 16 yr: 20-35 kg: 10 mg once daily, may increase to maximum of 20 mg once daily.  â‰¥35 kg: 20 mg once daily, may increase to maximum of 40 mg once daily. Elderly: May consider lower starting dose of 5-10 mg daily.


May be taken with or without food.


Symptoms: Hypotension and tachycardia; bradycardia may occur if there is vagal stimulation.  Treatment: Dialysability of Olmesartan Medoxomil is unknown; provide symptomatic and supportive therapy.


Pregnancy; biliary obstruction.

Special Precautions

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy.  Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected.  Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted.  May be associated with oliguria, progressive azotaemia, and acute renal failure.  Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency.  Caution in renal impairment; monitor serum creatinine and potassium levels periodically.  Avoid use in severe renal impairment and severe hepatic impairment.  Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy.  Patients with primary aldosteronism may not respond to angiotensin receptor antagonist.  Not recommended in lactation.

Adverse Drug Reaction(s)

Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis. Potentially Fatal: Acute renal failure.

Drug Interactions

Concurrent use with ACE inhibitors, potassium-sparing diuretics, potassium salts, and drugs that may increase serum potassium may increase the risk of hyperkalaemia.  Concomitant use with NSAIDs may decrease glomerular filtration synergistically; acute renal failure may occur.  Increased serum concentrations of lithium and toxicity when used with angiotensin receptor antagonist have been reported; avoid concomitant use of lithium and Olmesartan medoxomil.

Lab Interference

Increased creatine phosphokinase.

Pregnancy Category (FDA) 

Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk.


Oral:  Store at 20-25°C.


Olmesartan medoxomil is an ester prodrug for olmesartan.  It is hydrolysed to olmesartan during absorption from the GI tract.  Olmesartan is a selective and competitive angiotensin II Type 1 receptor antagonist and hence it blocks the vasocontrictor and aldosterone-secreting effects of angiotensin II.  Absorption: Bioavailability: About 26%.  Tmax: Reached within 1-2 hr.  Distribution: Vd: 17 L; protein binding: 99%.  Metabolism: Olmesartan medoxomil is hydrolysed in the GI tract to Olmesartan during absorption.  Excretion: Excreted as Olmesartan in faeces via the bile and in urine.  Terminal elimination half-life: About 13 hr.

ATC Classification

C09CA08 - olmesartan medoxomil; Belongs to the class of angiotensin II antagonists.  Used in the treatment of cardiovascular disease.


Search GoogleOlmesartan

Brand/Product Info

Total Products : 10          
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ABETIS ACI Ltd. Olmesartan medoxomil INN 10, 20 & 40mg Tablet (film-coated) 10mg x 30's, 20mg x 30's, 40mg x 30's: 150.60, 240.90 & 451.80 MRP
OLMECAR 20 Square Pharmaceuticals Ltd. Olmesartan Medoxomil 20mg Tablet 3x10's: 240.90 MRP
OLMECAR 40 Square Pharmaceuticals Ltd. Olmesartan Medoxomil 40mg Tablet 3x10's: 451.50 MRP
OLMESAN 20 Beximco Pharmaceuticals Ltd Olmesartan Medoxomil INN 20mg Tablet 30's: 240.00 MRP
OLMESAN 40 Beximco Pharmaceuticals Ltd Olmesartan Medoxomil INN 40mg Tablet 30's: 450.00 MRP
OLMETIC Drug International Ltd Olmesartan medoxomil INN 20mg Tablet (film-coated) 30's 240.00 MRP
OLMEZEST Sun Pharmaceutical (Bangladesh) Ltd. Olmesartan medoxomil INN 10, 20 & 40mg Tablet (film-coated) 30's each: 150.00, 241.50 & 450.00 MRP
OLSART Opsonin Pharma Limited Olmesartan medoxomil INN 20 & 40mg Tablet (film-coated) 30's each: 240.00 & 300.00 MRP
Xyotil 20 Incepta Pharmaceuticals Limited Olmesartan Medoxomil INN 20mg Tablet 10x3's:MRP 240 Tk
Xyotil 40 Incepta Pharmaceuticals Limited Olmesartan Medoxomil INN 40mg Tablet 10x3's:MRP 450 Tk

Gen. MedInfo


Tell your doctor if you are pregnant or plan to become pregnant. Do not take olmesartan if you are pregnant. If you become pregnant while you are taking olmesartan, stop taking olmesartan and call your doctor immediately. Olmesartan may cause death or serious injury to the fetus when taken in the last 6 months of pregnancy.


Why this medication is prescribed?

Olmesartan is used alone or in combination with other medications to treat high blood pressure in adults and children 6 years of age and older. Olmesartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. 

How should this medicine be used?

Olmesartan comes as a tablet to take by mouth. It is usually taken once a day with or without food. To help you remember to take olmesartan, take it at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olmesartan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If your child can not swallow a tablet, talk to your doctor or pharmacist. The pharmacist can prepare a liquid form of this medication for your child.

Your doctor will probably start you on a low dose of olmesartan and may increase your dose after 2 weeks.

Olmesartan controls high blood pressure but does not cure it. Your blood pressure may decrease during the first week of your treatment, but it may take up to 2 weeks before you notice the full benefit of olmesartan. Continue to take olmesartan even if you feel well. Do not stop taking olmesartan without talking to your doctor.

Other uses for this medicine

Olmesartan is also sometimes used to treat congestive heart failure (condition in which the heart is unable to pump enough blood to the rest of the body) and diabetic nephropathy (kidney disease in people with diabetes and high blood pressure). Talk to your doctor about the possible risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking olmesartan,

  • tell your doctor and pharmacist if you are allergic to olmesartan,any other medications, or any of the ingredients in olmesartan tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor if you have diabetes (high blood sugar) and you are taking. Your doctor will probably tell you not to take olmesartan if you have diabetes and you are also taking aliskiren.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention diuretics ('water pills') and potassium supplements. Your doctor may need to change the doses of your medication or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had heart failure, or kidney or liver disease.
  • tell your doctor if you are breast-feeding.
  • you should know that olmesartan may cause dizziness, light-headedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking olmesartan. To help avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.
  • you should know that diarrhea, vomiting, not drinking enough fluids, and sweating a lot can cause a drop in blood pressure, which may cause light-headedness and fainting. Tell your doctor if you have any of these problems or develop them during your treatment.

What special dietary instructions should I follow?

Do not use salt substitutes containing potassium without talking to your doctor. If your doctor prescribes a low-salt or low-sodium diet, follow these directions carefully.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Olmesartan may cause side effects. Tell your doctor if this symptom is severe or does not go away:

  • dizziness
  • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
  • hoarseness
  • difficulty breathing or swallowing

Some side effects can be serious. If you experience any of these symptoms or those listed in the SPECIAL PRECAUTIONS section, call your doctor immediately:

Olmesartan may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

 What should I know about storage and disposal of this medication?

 Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication.

 Symptoms of overdose may include

  • fainting
  • dizziness
  • fast or slow heartbeat

 What other information should I know?

Keep all appointments with your doctor and the laboratory. Your blood pressure should be checked regularly to determine your response to olmesartan.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies. 


Ref: U.S. Natl. Library of Medicine


 | See Brand Manufacturer's Prescribing Information | | OLMESARTAN |
Simple Breath Test Might Diagnose Heart Failure An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a...
Osteoporosis drug stops Breast cancer growth   News & Events News & Events     HIGHLIGHTS Osteoporosis drug stops growth of breast cancer...
Generic drug safety info loophole FDA plans to close generic drug safety info loophole The US Food and Drug Administration has announced plans to speed up the dissemination of...
Large trials unpublished   News & Events News & Events   HIGHLIGHTS Almost 1 in 3 of large clinical trials unpublished after...
TB activists boo Indian minister News & Events News & Events   HIGHLIGHTS TB activists at world conference boo Indian minister off...
Key bone marrow protein identified News & Events News & Events   HIGHLIGHTS Key bone marrow protein identified as potential new leukemia...